A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening Medical Device Investing
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Medical Device Investing
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 Life Science Investing
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 Life Science Investing
PharmaTher Enters into Collaboration Agreement for KetaMist to Advance Needle-Free Ketamine Treatment Toward FDA Approval Life Science Investing
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time Life Science Investing
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule Medical Device Investing
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology Congress 2026 Life Science Investing
